Skip to main content

Month: August 2024

Qifu Technology Announces Second Quarter and Interim 2024 Unaudited Financial Results, Announces Board Change and Raises Semi-Annual Dividend

SHANGHAI, Aug. 13, 2024 (GLOBE NEWSWIRE) — Qifu Technology, Inc. (NASDAQ: QFIN; HKEx: 3660) (“Qifu Technology” or the “Company”), a leading Credit-Tech platform in China, today announced its unaudited financial results for the second quarter and six months ended June 30, 2024, announced board change and raised semi-annual dividend. Second Quarter 2024 Business HighlightsAs of June 30, 2024, our platform has connected 160 financial institutional partners and 247.6 million consumers*1 with potential credit needs, cumulatively, an increase of 12.2% from 220.6 million a year ago. Cumulative users with approved credit lines*2 were 53.6 million as of June 30, 2024, an increase of 13.0% from 47.4 million as of June 30, 2023. Cumulative borrowers with successful drawdown, including repeat borrowers was 32.0 million as of June 30, 2024,...

Continue reading

HealthEquity Sets Date to Announce Second Quarter Results Presentation at Conferences

DRAPER, Utah, Aug. 13, 2024 (GLOBE NEWSWIRE) — HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA”) custodian, today announced plans to release its second quarter of fiscal 2025 financial results following the close of regular stock market trading hours on Tuesday, September 3, 2024. Following the news release, HealthEquity management plans to host a conference call for investors on Tuesday, September 3, 2024, at 4:30 p.m. Eastern Time during which management will review the Company’s second quarter results.HealthEquity Second Quarter Fiscal Year 2025 Results Conference CallDate: September 3, 2024Time: 4:30 p.m. Eastern Time / 2:30 p.m. Mountain TimeDial-In: 1-833-630-1956 (US and Canada) 1-412-317-1837 (International)Conference ID: HealthEquityWebcast: ir.healthequity.com   A...

Continue reading

Pieridae Releases Q2 2024 Financial and Operating Results and Revises 2024 Guidance

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES ORDISSEMINATION IN UNITED STATES CALGARY, Alberta, Aug. 13, 2024 (GLOBE NEWSWIRE) — Pieridae Energy Limited (“Pieridae” or the “Company”) (TSX: PEA) announces the release of its second quarter 2024 financial and operating results. Pieridae produced 30,861 boe/d and generated Net Operating Income (“NOI”)1 of $7.7 million during the second quarter of 2024. Pieridae’s management’s discussion and analysis (“MD&A”) and unaudited interim consolidated financial statements and notes for the quarter ended June 30, 2024 are available at www.pieridaeenergy.com and on SEDAR at www.sedarplus.ca. Darcy Reding, President and CEO stated “Pieridae’s robust commodity hedge portfolio resulted in $19.8 million of gains, offsetting the significant challenge created by extremely low AECO...

Continue reading

Algoma Steel Group Reports Fiscal First Quarter 2025 Financial Results

First Quarter Results In-Line with Previously Announced Outlook Completed Plate Mill Upgrade, Ramping Production Towards Expected Annual Run Rate Capacity of Over 650,000 NT Continued to Significantly De-risk Transformative Electric Arc Furnace Project as Construction Continues on Schedule Announces Intention to Relaunch Normal Course Issuer Bid SAULT STE. MARIE, Ontario, Aug. 13, 2024 (GLOBE NEWSWIRE) — Algoma Steel Group Inc. (NASDAQ: ASTL; TSX: ASTL) (“Algoma” or “the Company”), a leading Canadian producer of hot and cold rolled steel sheet and plate products, today announced results for its fiscal first quarter ended June 30, 2024. Unless otherwise specified, all amounts are in Canadian dollars. Business Highlights and Fiscal 2025 to Fiscal 2024 First Quarter ComparisonsConsolidated revenue of $650.5 million, compared to...

Continue reading

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi’s Adult Adipose Allogeneic (AAA) stem cell innovative programsStrengthened team with the appointment of Dr. George E. Peoples, MD, FACS, adjunct professor of Surgical Oncology at MD Anderson Cancer Center, to the company’s Board of Directors, and the addition of Mark Gilbert, MD, scientist emeritus at the National Institutes of Health (NIH), to its Medical Advisory BoardReceived a new U.S. patent for the company’s novel SuperNova technology, positioning Calidi to advance its CLD-201 program into the clinic. The patent covers a unique cancer treatment combining stem cells and a smallpox vaccine, strengthening Calidi’s position in developing innovative therapies for advanced solid tumorsSAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) —...

Continue reading

D-BOX Technologies Reports First Quarter Financial Results

D-BOX lays foundation for next phase of growth with new executive and cost structure, and improved credit agreement MONTRÉAL, Aug. 13, 2024 (GLOBE NEWSWIRE) — D-BOX Technologies Inc. (“D-BOX” or the “Corporation”) (TSX: DBO) a world leader in haptic and immersive experiences, today reported financial results for the first quarter ended June 30, 2024. All dollar amounts are expressed in Canadian currency. Q1 FISCAL 2025 HIGHLIGHTS(Compared to Q1 fiscal 2024)Total revenues decreased 16% to $8.8 million due to continued softness in the theatrical market and timing differences in the simulation and training market Sim racing revenues increased $1.1 million 4 net new screens installed, bringing the total number of active D-BOX cinema screens to 933 as at June 30, 2024 Adjusted EBITDA was $263 thousand versus $1.3 million...

Continue reading

Element Reports Record Second Quarter Results, Raises Full-Year 2024 Guidance, and Announces Strategic Acquisition

Amounts in US$ unless otherwise notedRecord quarterly net revenue of US$274.6 million driving adjusted EPS of US$0.29 and adjusted free cash flow per share of US$0.38Robust net revenue growth of 14.1% year-over-year led by a double-digit increase across net financing and services revenues; and up 4.6% from a strong Q1 2024Reports record origination volume; up 28.2% from Q1 2024 and up 4.6% from Q2 2023Raises full-year 2024 guidance on most metrics as a result of robust first half 2024 performanceUnveils first-ever Purpose statement: Move the World Through Intelligent MobilityAccelerates digitization and automation capabilities with the execution of a definitive agreement for the acquisition of Autofleet Solutions Ltd. (“Autofleet”)TORONTO, Aug. 13, 2024 (GLOBE NEWSWIRE) — Element Fleet Management Corp....

Continue reading

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

In-licensed SYN-2510/IMM2510, a potentially best-in-class PD-L1xVEGF bispecific antibody, and SYN-27M/IMM27M, a next-generation ADCC-enhanced anti-CTLA-4 antibody Entered into a 15-year lease for our cell therapy manufacturing facility to AstraZeneca Pharmaceuticals LPDALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2024 financial results and provided a corporate update. “We have expanded our pipeline with a pair of clinical-stage, potentially best-in-class therapeutics by in-licensing SYN-2510 and SYN-27M,” said Bronson Crouch, CEO of Instil. “By executing a 15-year lease of our Tarzana cell therapy manufacturing facility, we have strengthened our financial foundation...

Continue reading

DZS Completes Restatement of 2022 and Q1 2023 Financial Results and Files Reports for Remaining Periods in 2023

DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) — DZS (OTC: DZSI), a developer of Network Edge, Connectivity and Cloud Software solutions enabling gigabit broadband everywhere, today announced that it has filed with the SEC its restated financial results for the periods from the first quarter of 2022 through the first quarter of 2023 as well as its remaining periods in 2023. DZS is now current with its Form 10-Q and 10-K filings with the SEC through 2023. “We took an extremely thorough approach to the restatement process, and now have completed the restatements with respect to 2022 and the first quarter of 2023, as well as the reports for the remaining periods in 2023,” said Charlie Vogt, President and CEO, DZS. “Following a strong top line revenue growth environment in 2021 and 2022, 2023 represented a challenging market and business environment....

Continue reading

Credicorp Ltd.: Credicorp Corrects Certain Accumulated Ratios in 2Q24 Earnings Materials and Reaffirms 1H24 Financials and 2024 Guidance

Lima, Aug. 13, 2024 (GLOBE NEWSWIRE) — Lima, PERU, August 13, 2024 – Credicorp Ltd. (“Credicorp” or “the Company”) (NYSE: BAP | BVL: BAP) announces to its shareholders and the market, corrections to four ratios published in its 2Q24 Earnings Materials. These amendments are attributable to miscalculations on certain accumulated performance indicators. Below is a table including the reported and corrected indicators, presented on the Company´s 2Q24 Earnings Release.Performance Indicator Originally Reported Figure Corrected Figure Location in Earnings Release1H24 ROE 17.2% 17.6% Pages 3 and 111H24 Funding cost 3.16% 2.90% Page 111H24 Operating expenses / Total average assets 7.4% 3.7% Page 111H23 Operating Expenses / Total average assets 7.1% 3.5% Page 11The above-mentioned corrections do not affect the Company’s...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.